References

antibiotics

Антибиотики и Химиотерапия

Antibiot Khimioter = Antibiotics and Chemotherapy

0235-2990

ООО «Издательство ОКИ»

10.37489/0235-2990-2025-70-11-12-75-91

PHZICT

antibiotics-1314

Research Article

ОБЗОРЫ

REVIEWS

Ванкомицинорезистентные клинические штаммы Enterococcus spp. и Staphylococcus aureus

Vancomycin-Resistant Clinical Strains of Enterococcus spp. and Staphylococcus aureus

https://orcid.org/0009-0008-9533-5941

Лебедькова

А. А.

Lebedkova

A. A.

Лебедькова Александра Андреевна — младший научный сотрудник лаборатории биологической безопасности.

Оболенск

Alexandra A. Lebedkova — Junior Researcher, Biological Safety Laboratory, State Research Center for Applied Microbiology and Biotechnology of Rospotrebnadzor (Russian Federal State Agency for Health and Consumer Rights).

Obolensk

https://orcid.org/0000-0002-2829-5117

Хохлова

О. Е.

Khokhlova

O. E.

Хохлова Ольга Евгеньевна — д. б. н., главный научный сотрудник отдела молекулярной микробиологии, профессор.

Оболенск

Scopus ID 54986821300

Olga E. Khokhlova — D. Sc. in Biology, Chief Researcher, Department of Molecular Microbiology, Professor, State Research Center for Applied Microbiology and Biotechnology of Rospotrebnadzor (Russian Federal State Agency for Health and Consumer Rights).

Obolensk

Scopus ID 54986821300

khokhlovaol@mail.ru

https://orcid.org/0000-0001-9637-7790

Коломбет

Л. В.

Kolombet

L. V.

Коломбет Любовь Васильевна — д. б. н., ученый секретарь.

Оболенск

Lyubov V. Kolombet — D. Sc. in Biology, Academic Secretary, State Research Center for Applied Microbiology and Biotechnology of Rospotrebnadzor (Russian Federal State Agency for Health and Consumer Rights).

Obolensk

https://orcid.org/0000-0002-2006-9131

Карцев

Н. Н.

Kartsev

N. N.

Карцев Николай Николаевич — к. м. н., заместитель директора по лабораторной деятельности; ведущий научный сотрудник отдела молекулярной микробиологии.

Оболенск

Scopus ID 55601168400

Nikolay N. Kartsev — Ph. D. in Medicine, Deputy Director for Laboratory Activities; Leading Researcher, Department of Molecular Microbiology, State Research Center for Applied Microbiology and Biotechnology, Rospotrebnadzor (Russian Federal State Agency for Health and Consumer Rights).

Obolensk

Scopus ID 55601168400

ФБУН Государственный научный центр прикладной микробиологии и биотехнологии РоспотребнадзораРоссияState Research Center for Applied Microbiology and Biotechnology of RospotrebnadzorRussian Federation

2025

04032026

7011-127591

2026

Лебедькова А.А., Хохлова О.Е., Коломбет Л.В., Карцев Н.Н.

Lebedkova A.A., Khokhlova O.E., Kolombet L.V., Kartsev N.N.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.antibiotics-chemotherapy.ru/jour/article/view/1314

Ванкомицинорезистентные энтерококки (VRE) представляют серьёзную угрозу для общественного здравоохранения в связи с их высокой устойчивостью к антибиотикам, способностью вызывать тяжёлые инфекции и рост смертности в связи с ограничением терапевтических возможностей. В связи с этим изучение молекулярно-генетических характеристик ванкомицинорезистентных штаммов приобретает особую актуальность. Метициллинорезистентный золотистый стафилококк (MRSA) является основным полирезистентным внутрибольничным патогеном. Ванкомицин по-прежнему остаётся золотым стандартом терапии инвазивных инфекций, вызванных MRSA наряду с некоторыми другими анти-MRSA препаратами, такими как тейкопланин, линезолид и даптомицин. Ранее к ванкомицинорезистентным MRSA (VRSA) относили штаммы с МПК I 16 мкг/мл, однако у пациентов число случаев обусловленных такими штаммами всё ещё ограничено. С клинической точки зрения ванкомицин становится менее эффективным в отношении инфекций, вызванных штаммами MRSA с МПК к ванкомицину I 1,5– 2 мкг/мл. Выделяют категории штаммов S. aureus с промежуточной чувствительностью к ванкомицину (VISA) и гетерогенной чувствительностью к ванкомицину VISA (hVISA), как правило, относящиеся к HA-MRSA, часть из которых на сегодняшний день отнесены EUCAST к ванкомицинорезистентным.

Vancomycin-resistant enterococci (VRE) pose a serious public health threat due to their high antibiotic resistance, ability to cause severe infections, and increased mortality due to limited therapeutic options. Therefore, studying the molecular genetic characteristics of vancomycin-resistant strains is particularly important. Methicillin-resistant Staphylococcus aureus (MRSA) is a major multidrug-resistant nosocomial pathogen. Regarding chemotherapy against invasive MRSA infections, vancomycin still remains a gold standard, in addition to some other anti-MRSA agents, such as teicoplanin, linezolid, and daptomycin. Previously, vancomycin-resistant MRSA (VRSA) was defined as strains with an MICs I 16 µg/mL; however, the number of cases caused by these strains in patients remains limited. Clinically, infections from strains with MICs of I 1.5 µg/mL, even with albeit susceptible MICs (⇄ 2 µg/mL), respond poorly to vancomycin. Some of those bacteria have been bacteriologically characterized as vancomycin-intermediate S. aureus (VISA) and heterogeneous VISA (hVISA), generally with HA-MRSA genetic backgrounds, which are currently classified by EUCAST as vancomycin-resistant.

антибиотикорезистентностьклинические штаммы бактерийванкомицинорезистентные энтерококкиванкомицинорезистентный золотистый стафилококк

antibiotic resistanceclinical bacterial strainsvancomycin-resistant enterococcivancomycin-resistant Staphylococcus aureus

Работа проведена в рамках Отраслевой программы Роспотребнадзора.

References1

Баранцевич Н. Е., Волкова С. В., Зарицкий А. Ю., Баранцевич Е. П. Антимикробная резистентность энтерококков. Антибиотики и химиотерапия. 2021; 66: 9–10: 12–16. doi: https://doi.org/10.24411/0235-2990-2021-66-9-10-12-16.

Barantsevich N. E., Volkova S. V., Zaritsky A. Yu., Barantsevich E. P. Antimicrobial resistance in Enterococci. Antibiotiki i Khimioter = Antibiotics and Chemotherapy. 2021; 66: 9–10: 12–16. doi: 10.24411/0235-2990-2021-66-9-10-12-16. (in Russian)

Zaheer R., Cook S. R., Barbieri R., Goji N., Cameron A., Petkau A. et al. Author correction: surveillance of Enterococcus spp. reveals distinct species and antimicrobial resistance diversity across a One-Health continuum. Sci Rep. 2020; 10 (1): 13401. doi: 10.1038/s41598-020-69044-5.

Hollenbeck B. L., Rice L. B. Intrinsic and acquired resistance mechanisms in enterococcus. Virulence. 2012; 3 (5): 421–433. doi: 10.4161/viru.21282.

Farman M., Yasir M., Al-Hindi R. R., Farraj S. A., Jiman-Fatani A. A., Alawi M., Azhar E. I. Genomic analysis of multidrug-resistant clinical Enterococcus faecalis isolates for antimicrobial resistance genes and virulence factors from the western region of Saudi Arabia. Antimicrob Resist Infect Control. 2019; 8: 55. doi: 10.1186/s13756-019-0508-4.

Suppli M., Aabenhus R., Harboe Z. B., Andersen L. P., Tvede M., Jensen J. U. Mortality in enterococcal bloodstream infections increases with inappropriate antimicrobial therapy. Clin Microbiol Infect. 2011; 17 (7): 1078–1083. doi: 10.1111/j.1469-0691.2010.03394.x.

Billington E. O., Phang S. H., Gregson D. B., Pitout J. D., Ross T., Church D. L. et al. Incidence, risk factors, and outcomes for Enterococcus spp. blood stream infections: a population-based study. Int J Infect Dis. 2014; 26: 76–82. doi: 10.1016/j.ijid.2014.02.012.

Hota S., Patil S. R., Mane P. M. Enterococcus: understanding their resistance mechanisms, therapeutic challenges, and emerging threats. Cureus. 2025 Feb 25; 17 (2): e79628. doi: 10.7759/cureus.79628.

Miller W. R., Murray B. E., Rice L. B., Arias C. A. Resistance in vancomycin-resistant enterococci. Infect Dis Clin North Am. 2020 Dec; 34 (4): 751–771. doi: 10.1016/j.idc.2020.08.004.

Shrestha S., Kharel S., Homagain S., Aryal R., Mishra S. K. Prevalence of vancomycin-resistant enterococci in Asia — A systematic review and meta-analysis. J Clin Pharm Ther. 2021 Oct; 46 (5): 1226–1237. doi: 10.1111/jcpt.13383. Epub 2021 Feb 25.

European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU/EEA (EARS-Net)-Annual Epidemiological Report 2019. Stockholm: ECDC; 2020.

Cairns K. A., Udy A. A., Peel T. N., Abbott I. J., Dooley M. J., Peleg A. Y. Therapeutics for vancomycin-resistant enterococcal bloodstream infections. Clin Microbiol Rev. 2023 Jun 21; 36 (2): e0005922. doi: 10.1128/cmr.00059-22. Epub 2023 Apr 17.

Cimen C., Berends M. S., Bathoorn E., Lokate M., Voss A., Friedrich A. W., Glasner C., Hamprecht A. Vancomycin-resistant enterococci (VRE) in hospital settings across European borders: a scoping review comparing the epidemiology in the Netherlands and Germany. Antimicrob Resist Infect Control. 2023 Aug 12; 12 (1): 78. doi: 10.1186/s13756-023-01278-0.

Miller W. R., Murray B. E., Rice L. B., Arias C. A. Resistance in Vancomycin-Resistant Enterococci Infect Dis Clin North Am. 2020 Dec; 34 (4): 751–771. doi: 10.1016/j.idc.2020.08.004.

Raven K. E., Reuter S., Gouliouris T., Reynolds R., Russell J. E., Brown N. M., Török M. E., Parkhill J., Peacock S. J. Genome-based characterization of hospital-adapted Enterococcus faecalis lineages. Nat Microbiol. 2016; 1 (3): 15033. doi: 10.1038/nmicrobiol.2015.33.

Galloway-Peña J., Roh J. H., Latorre M., Qin X., Murray B. E. Genomic and SNP analyses demonstrate a distant separation of the hospital and community-associated clades of Enterococcus faecium. PLoS One. 2012; 7 (1): e30187. doi: 10.1371/journal.pone.0030187.

Gouliouris T., Raven K. E., Ludden C., Blane B., Corander J., Horner C. S., Hernandez-Garcia J., Wood P., Hadjirin N. F., Radakovic M., Holmes M. A., de Goffau M., Brown N. M., Parkhill J., Peacock S. J. Genomic surveillance of Enterococcus faecium reveals limited sharing of strains and resistance genes between livestock and humans in the United Kingdom. mBio. 2018; 9 (6): e01780–18. doi: 10.1128/mBio.01780-18.

Staphylococcus aureus basics. https://www.cdc.gov/staphylococcus-aureus/about/index.html

Dantes R., Mu Yi., Belflower R., Aragon D., Dumyati G., Harrison L. H., Lessa F. C., Lynfield R., Nadle J., Petit S., Ray S. M., Schaffner W., Townes J., Fridkin S. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med. 2013 November 25; 173 (21): 1970–1978. doi: 10.1001/jamainternmed.2013.10423.

David M. Z., Daum R. S. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev. 2010; 23: 616–687. doi: 10.1128/cmr.00081-09.

Методические рекомендации. Метициллинрезистентные Staphylococcus aureus — возбудители внутрибольничных инфекций: идентификация и генотипирование, 2006.

Metodicheskie rekomendatsii. Metitsillinrezistentnye Staphylococcus aureus — vozbuditeli vnutribol'nichnykh infektsij: identifikatsiya i genotipirovanie, 2006. (in Russian)

GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study. 2019. Lancet. 2022; 400: 10369: 2221–2248. doi: 10.1016/S0140-6736(22)02185-7.

Laupland K. B., Lyytikäinen O., Søgaard M., Kennedy K. J., Knudsen J. D., Ostergaard C. et al. The changing epidemiology of Staphylococcus aureus bloodstream infection: a multinational population-based surveillance study. Clin Microbiol Infect. 2013; 19 (5): 465–471. doi: 10.1111/j.1469-0691.2012.03903.x.

Kallen A. J., Mu Y., Bulens S., Reingold A., Petit S., Gershman K. et al. Health care-associated invasive MRSA infections, 2005–2008. JAMA. 2010; 304 (6): 641–8. doi: 10.1001/jama.2010.1115.

Bai A. D., Lo C. K. L., Komorowski A. S., Suresh M., Guo K., Gard A. et al. Staphylococcus aureus bacteraemia mortality: a systematic review and metaanalysis. Clin Microbiol Infect. 2022; 28 (8): 1076–1084. doi: 10.1016/j.cmi.2022.03.015.

Gill J. L., Hedge J., Wilson D. J., Maclean R. C. Evolutionary processes driving the rise and fall of Staphylococcus aureus ST239, a dominant hybrid pathogen mBio. 2021; 12 (6): e0216821. doi: 10.1128/mBio.02168-21.

Клясова Г. А., Федорова А. В., Фролова И. Н., Хрульнова С. А., Ветохина А. В., Капорская Т. С., Скоробогатова Е. В., Молчанова И. В., Поспелова Т. И., Крайнова Л. Е., Шушурина С. Е., Хорева О. Е., Звёздкина Н. Н., Куцевалова О. Ю. Антибиотикорезистентность госпитальных штаммов Enterococcus spp., выделенных из гемокультуры больных опухолями системы крови: результаты многоцентрового исследования. КМАХ 2018; 20 (2): 142–149. https://cyberleninka.ru/article/n/antibiotikorezistentnost-gospitalnyh-shtammov-enterococcus-spp-vydelennyh-iz-gemokultury-bolnyh-opuholyami-sistemy-krovi-rezultaty.

Klyasova G. A., Fedorova A. V., Frolova I. N., Khrul'nova S. A., Vetokhina A. V., Kaporskaya T. S., Skorobogatova E. V., Molchanova I. V., Pospelova T. I., Krajnova L. E., Shushurina S. E., Khoreva O. E., Zvezdkina N. N., Kutsevalova O. Yu. Antibiotikorezistentnost' gospital'nykh shtammov Enterococcus spp., vydelennykh iz gemokul'tury bol'nykh opukholyami sistemy krovi: rezul'taty mnogotsentrovogo issledovaniya. KMAKh 2018; 20 (2): 142–149. https://cyberleninka.ru/article/n/antibiotikorezistentnost-gospitalnyh-shtammov-enterococcus-spp-vydelennyh-iz-gemokultury-bolnyh-opuholyami-sistemy-krovi-rezultaty. (in Russian)

Giulieri S. G., Guerillot R., Holmes N. E., Baines S., Hachani A., Hayes A. S. et al. A statistical genomics framework to trace bacterial genomic predictors of clinical outcomes in Staphylococcus aureus bacteremia. Cell Rep. 2023; 42 (9): 113069. doi: 10.1016/j.celrep.2023.113069.

Leclercq R., Derlot E., Duval J., Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med. 1988 Jul 21; 319 (3): 157–161. doi: 10.1056/NEJM198807213190307. PMID: 2968517.

Uttley A. H., Collins C. H., Naidoo J. Vancomycin-resistant enterococci. Lancet. 1988; 1: 57–58. doi: 10.1016/s0140-6736(88)91037-9.

Kliasova G., Sidorenko S., Speranskaja L., Fedorova A. V. Detection of vanb2 in Enterococcus gallinarum in Moscow, Russia. International Journal Antimicrobial Agents. 2004; 24 (2): 79. https://elibrary.ru/item.asp?id=24138532

Zhou X., Willems R. J.L., Friedrich A. W., Rossen J. W.A., Bat-hoorn E. Enterococcus faecium: from microbiological insights to practical recommendations for infection control and diagnostics. Antimicrob Resist Infect Control. 2020; 9 (1): 130. Epub 2020 Aug 10. doi: 10.1186/s13756-020-00770-1.

Fedorova A. V., Cherkashin E., Kliasova G., Tishkov V. V., Briliantova A., Rezvan S., Sidorenko S. First detection of vancomycin-resistant enterococci in Russia: genetic background. Clinical Microbiology and Infection. 2006; 12 (S4): 1819. https://elibrary.ru/item.asp?id=24138523.

Bagirova N. S., Dmitrieva N. V. Enterococcal bacteraemia in patients with haematological malignancies. Clin Microbiol Infect. 2006; 12 (S4): 8: 699.

Любимова А. В., Зуева Л. П., Колоджиева В. В., Гончаров А. Е. Ванкомицин-резистентные энтерококки в отделениях реанимации новорождённых. Эпидемиология и вакцинопрофилактика. 2011; 4 (59): 27–30. https://cyberleninka.ru/article/n/vankomitsin-rezistentnye-enterokokki-v-otdeleniyah-reanimatsii-novorozhdennyh/viewer.

Lyubimova A. V., Zueva L. P., Kolodzhieva V. V., Goncharov A. E. Vankomitsin-rezistentnye enterokokki v otdeleniyakh reanimatsii novorozhdennykh. Epidemiologiya i Vaktsinoprofilaktika. 2011; 4 (59): 27–30. https://cyberleninka.ru/article/n/vankomitsin-rezistentnye-enterokokki-v-otdeleniyah-reanimatsii-novorozhdennyh/viewer. (in Russian)

Brilliantova A. N., Kliasova G. A., Mironova A. V., Tishkov V. I., Novichkova G. A., Bobrynina V. O., Sidorenko S. V. et al. Spread of vancomycin-resistant Enterococcus faecium in two haematological centres in Russia. Intern J Antimicrob Agents. 2010; 35 (2): 177–181. doi: 10.1016/j.ijantimicag.2009.10.006.

Dai D., Wang H., Xu X., Chen C., Song C., Jiang D., Du P., Zhang Y., Zeng H. The emergence of multi-resistant Enterococcus faecalis clonal complex, CC4, causing nosocomial infections. J Med Microbiol. 2018 Aug; 67 (8): 1069–1077. doi: 10.1099/jmm.0.000761. Epub 2018 Jun 20. PMID: 29923823.

Zalipour M., Esfahani B. N., Halaji M., Azimian A., Havaei S. A. Molecular characterization of vancomycin-resistant Enterococcus faecalis among inpatients at iranian university hospitals: clonal dissemination of ST6 and ST422. Infect Drug Resist. 2019 Sep 25; 12: 3039–3047. doi: 10.2147/IDR.S217718. PMID: 31576154; PMCID: PMC6768148.

Ben Braïek O., Smaoui S. Enterococci: between emerging pathogens and potential probiotics. Biomed Res Int. 2019 May 23; 2019: 5938210. doi: 10.1155/2019/5938210. PMID: 31240218; PMCID: PMC6556247.

Werner G., Neumann B., Weber R. E., Kresken M., Wendt C., Bender J. K.; VRE study group. Thirty years of VRE in Germany — «expect the unexpected»: the view from the national reference centre for Staphylococci and Enterococci Drug Resist Updat. 2020 Dec; 53: 100732. doi: 10.1016/j.drup.2020.100732.

Monecke S., Slickers P., Gawlik D., Müller E., Reissig A., Ruppelt-Lorz A., Akpaka P. E. et al. Molecular typing of ST239-MRSA-III from diverse geographic locations and the evolution of the SCCmec III element during its intercontinental spread. Front Microbiol. 2018; 9: 436. doi: 10.3389/fmicb.2018.01436.

Lee A. S.,, de Lencastre H., Garau J., Kluytmans J., Malhotra-Kumar S., Peschel A., Harbarth S. Methicillin-resistant Staphylococcus aureus. Nat Rev Dis Primers. 2018; 31 (4): 1–23. doi: 10.1038/nrdp.2018.33.

Бухарин О. В., Валышева И. В., Карташова О. Л., Сычева М. В. Характеристика вирулентного потенциала клинических изолятов энтерококков. Журнал микробиологии, эпидемиологии и иммунобиологии. 2013. 3: 12–18.

Bukharin O. V., Valysheva I. V., Kartashova O. L., Sycheva M. V. Kharakteristika virulentnogo potentsiala klinicheskikh izolyatov enterokokkov. Zhurnal Mikrobiologii, Epidemiologii i Immunobiologii. 2013. 3: 12–18. (in Russian)

Narenji H., Teymournejad O., Rezaee M. A., Taghizadeh S., Mehramuz B., Aghazadeh M.et al. Antisense peptide nucleic acids against ftsZ and efaA genes inhibit growth and biofilm formation of Enterococcus faecalis. Microb Pathog. 2020; 139: 103907. doi: 10.1016/j.micpath.2019.103907.

Kiruthiga A., Padmavathy K., Shabana P., Naveenkumar V., Gnanadesikan S., Malaiyan J. Improved detection of esp, hyl, asa1, gelE, cylA virulence genes among clinical isolates of Enterococci. BMC Res Notes. 2020 Mar 20; 13 (1): 170. doi: 10.1186/s13104-020-05018-0. PMID: 32197635; PMCID: PMC7085142.

Strateva T., Atanasova D., Savov E., Petrova G., Mitov I. Incidence of virulence determinants in clinical Enterococcus faecalis and Enterococcus faecium isolates collected in Bulgaria. Braz J Infect Dis. 2016 Mar–Apr; 20 (2): 127–133. doi: 10.1016/j.bjid.2015.11.011. Epub 2016 Feb 2. PMID: 26849965; PMCID: PMC9427613.

Миронова А. В., Коршукова О. А. Факторы вирулентности энтерококков. Здоровье. Медицинская экология. Наука. 2015. 2 (60): 73–78. https://cyberleninka.ru/article/n/faktory-virulentnosti-enterokokkov-1/viewer.

Mironova A. V., Korshukova O. A. Faktory virulentnosti enterokokkov. Zdorov'e. Meditsinskaya ekologiya. Nauka. 2015. 2 (60): 73–78. https://cyberleninka.ru/article/n/faktory-virulentnosti-enterokokkov-1/viewer. (in Russian)

Eichel V. M., Last K., Brühwasser C., von Baum H., Dettenkofer M., Götting T., Grundmann H., Güldenhöven H., Liese J., Martin M., Papan C., Sadaghiani C., Wendt C., Werner G., Mutters N. T. Epidemiology and outcomes of vancomycin-resistant enterococcus infections: a systematic review and meta-analysis. J Hosp Infect. 2023 Nov; 141: 119–128. doi: 10.1016/j.jhin.2023.09.008. Epub 2023 Sep 19.

Gill S. R., Fouts D. E., Archer G. L., Mongodin E. F., Deboy R. T., Ravel J., Paulsen I. T., Kolonay J. F., Brinkac L., Beanan M., Dodson R. J., Daugherty S. C., Madupu R., Angiuoli S. V., Durkin A. S., Haft D. H., Vamathevan J., Khouri H., Utterback T., Lee C., Dimitrov G., Jiang L., Qin H., Weidman J., Tran K., Kang K., Hance I. R., Nelson K. E., Fraser C. M. Insights on evolution of virulence and resistance from the complete genome analysis of an early methicillin-resistant Staphylococcus aureus strain and a biofilm-producing methicillin-resistant Staphylococcus epidermidis strain. J Bacteriol. 2005 Apr; 187 (7): 2426–38. doi: 10.1128/JB.187.7.2426-2438.2005. PMID: 15774886; PMCID: PMC1065214.

Harper L., Balasubramanian D., Ohneck E. A., Sause W. E., Chapman J., Mejia-Sosa B., Lhakhang T., Heguy A., Tsirigos A., Ueberheide B., Boyd J. M., Lun D. S., Torres V. J. Staphylococcus aureus responds to the central metabolite pyruvate to regulate virulence. mBio. 2018 Jan 23; 9 (1): e02272–17. doi: 10.1128/mBio.02272-17. PMID: 29362239; PMCID: PMC5784258.

Balasubramanian D., Harper L., Shopsin B., Torres V. J. Staphylococcus aureus pathogenesis in diverse host environments. Pathog Dis. 2017 Jan 1; 75 (1): ftx005. doi: 10.1093/femspd/ftx005. PMID: 28104617; PMCID: PMC5353994.

Painter K. L., Krishna A., Wigneshweraraj S., Edwards A. M. What role does the quorum-sensing accessory gene regulator system play during Staphylococcus aureus bacteremia? Trends Microbiol. 2014 Dec; 22 (12): 676–685. doi: 10.1016/j.tim.2014.09.002. Epub 2014 Oct 6. PMID: 25300477.

Wang X., Li X., Liu W., Huang W., Fu Q., Li M. Molecular characteristic and virulence gene profiles of community-associated methicillin-resistant Staphylococcus aureus isolates from pediatric patients in Shanghai, China. Front Microbiol. 2016 Nov 15; 7: 1818. doi: 10.3389/fmicb.2016.01818. PMID: 27895635; PMCID: PMC5108810.

52 Wang X., Li X., Liu W., Huang W., Fu Q., Li M. Molecular characteristic and virulence gene profiles of community-associated methicillin-resistant Staphylococcus aureus isolates from pediatric patients in Shanghai, China. Front Microbiol. 2016 Nov 15; 7: 1818. doi: 10.3389/fmicb.2016.01818. PMID: 27895635; PMCID: PMC5108810.

Aung M. S., Urushibara N., Kawaguchiya M., Hirose M., Ito M., Habadera S., Kobayashi N. Clonal diversity of methicillin-resistant Staphylococcus aureus (MRSA) from bloodstream infections in northern Japan: Identification of spermidine N-acetyltransferase gene (speG) in staphylococcal cassette chromosomes (SCCs) associated with type II and IV SCCmec. J Glob Antimicrob Resist. 2021 Mar; 24: 207–214. doi: 10.1016/j.jgar.2020.12.008. Epub 2020 Dec 26. PMID: 33373735.

Гостев В. В., Гончаров А. Е., Грачева М. А., Сидоренко С. В. Распространение генов комплекса immune evasion cluster и других факторов вирулентности у Staphylococcus aureus. Клиническая микробиология и антимикробная химиотерапия. 2013; 4: 270–278.

Gostev V. V., Goncharov A. E., Gracheva M. A., Sidorenko S. V. Rasprostranenie genov kompleksa immune evasion cluster i drugikh faktorov virulentnosti u Staphylococcus aureus. Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioterapiya. 2013; 4: 270–278. (in Russian)

Hau S. J., Sun J., Davies P. R., Frana T. S., Nicholson T. L. Comparative prevalence of immune evasion complex genes associated with β-hemolysin converting bacteriophages in MRSA ST5 isolates from Swine, Swine Facilities, humans with swine contact, and humans with no swine contact. PLoS One. 2015 Nov 10; 10 (11): e 0142832. doi: 10.1371/journal.pone.0142832.

Riccardi N., Monticelli J., Antonello R. M., Di Lallo G., Frezza D., Luzzati R., Di Bella S. Therapeutic options for infections due to vanb genotype vancomycin-resistant enterococci. Microb Drug Resist. 2021 Apr; 27 (4): 536–545. doi: 10.1089/mdr.2020.0171.

Miller W. R., Murray B. E., Rice L. B., Arias C. A. Resistance in vancomycin-resistant enterococci resistance in vancomycin-resistant enterococci. Infect Dis Clin North Am. 2020 Dec; 34 (4): 751–771. doi: 10.1016/j.idc.2020.08.004.

Monaco M., de Araujo F. P., Cruciani M., Coccia E. M., Pantosti A. Worldwide epidemiology and antibiotic resistance of Staphylococcus aureus. Curr Top Microbiol Immunol. 2017; 409: 21–56. doi: 10.1007/82_2016_3.

Bakthavatchalam Y. D., Babu P., Munusamy E., Dwarakanathan H. T., Rupali P., Zervos M. et al. Genomic insights on heterogeneous resistance to vancomycin and teicoplanin in methicillin-resistant Staphylococcus aureus: A fi rst report from South India. PLoS One. 2019; 14 (12): e0227009. doi: 10.1371/journal.pone.0227009.

Matsuo M., Yamamoto N., Hishinuma T., Hiramatsu K. Identifi cation of a novel gene associated with high-level β-lactam resistance in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3 and methicillin-resistant S. aureus strain N315. Antimicrob Agents Chemother. 2019; 63 (2): e00712–18. doi: 10.1128/AAC.00712-18.

Gao C., Dai Y., Chang W., Fang C., Wang Z., Ma X. VraSR has an important role in immune evasion of Staphylococcus aureus with low level vancomycin resistance. Microbes Infect. 2019; 21 (8– 9): 361–367. doi: 10.1016/j.micinf.2019.04.003.

McGuinness W. A., Malachowa N., DeLeo F. R. Vancomycin resistance in Staphylococcus aureus Yale J Biol Med. 2017 Jun 23; 90 (2): 269–281. eCollection 2017 Jun. PMID: 28656013 PMCID: PMC5482303.

Berti A. D., Theisen E., Sauer J.-D., Nonejuie P., Olson J., Pogliano J., Sakoulas G., Nizet V., Proctor R. A., Rose W. E. Penicillin binding protein 1 is important in the compensatory response of Staphylococcus aureus to daptomycin-induced membrane damage and is a potential target for β-lactam–daptomycin synergy. Antimicrob Agents Chemother 60: 451–458. doi: 10.1128/AAC.02071-15.

Lee A. S., de Lencastre H., Garau J., Kluytmans J., Malhotra-Kumar S., Peschel A., Harbarth S. Methicillin-resistant Staphylococcus aureus. Nat Rev Dis Primers. 2018; 31: 418033. doi: 10.1038/nrdp.2018.33.

Mlynarczyk-Bonikowska B., Kowalewski C., Krolak-Ulinska A., Marusza W. Molecular mechanisms of drug resistance in Staphylococcus aureus. Int J Mol Sci. 2022, 23, 8088. doi: 10.3390/ijms23158088.

Shariati A., Dadashi M., Moghadam M. T., van Belkum A., Yaslianifard S., Darban-Sarokhalil D. Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis. doi: 10.1038/s41598-020-69058-z.

Howden B. P., Davies J. K., Johnson P. D.R., Stinear T. P., Grayson M. L. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection and clinical implications. Clin Microbiol Rev. 2010; 23 (1): 99–139. doi: 10.1128/CMR.00042-09.

Walsh T. R., Bolmstrom A., Qwarnstrom A., Ho P., Wootton M., Howe R. A., MacGowan A. P., Diekema D. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol. 2001; 39: 7: 2439—2444. doi: 10.1128/JCM.39.7.2439-2444.2001.

Wi Y. M., Kim J. M., Joo E. J., Ha Y. E., Kang C. I., Ko K. S., Chung D. R., Song J. H., Peck K. R. High vancomycin minimum inhibitory concentration is a predictor of mortality in methicillin-resistant Staphylococcus aureus bacteraemia. Int J Antimicrob Agents. 2012; 40: 2: 108–113. doi: 10.1016/j.ijantimicag.2012.04.003.

LSI. Performance Standards for Antimicrobial Susceptibility Testing — Twenty-Nineth Edition: M100. 2019.

Wootton M. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother. 2001; 47: 399–403. doi: 10.1093/jac/47.4.399.

Cheng X., Zhou J., Yuan F., Ma J., Guo S., Su J. Diagnostic value of BHI-V4 for heterogeneous and vancomycin-intermediate Staphylococcus aureus isolates: a systematic review and metaanalysis. BMC Infect Dis. 2024; 24: 494. doi: 10.1186/s12879-024-09274-4.

Musta A. C., Riederer K., Shemes S., Chase P., Jose J., Johnson L. B., Khatib R. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol. 2009; 47: 6: 1640—1644. doi: 10.1128/JCM.02135-08.

Strauss L., Stegger M., Akpaka P. E., Alabi A., Breurec S., Coombs G. et al. Origin, evolution, and global transmission of community-acquired Staphylococcus aureus ST8. Proc Natl Acad Sci U S A. 2017; 114 (49): E10596–E10604. doi: 10.1073/pnas.1702472114.

Satola S. W., Farley M. M., Anderson K. F., Patel J. B. Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method. J Clin Microbiol 2011; 49: 177–83. doi: 10.1128/JCM.01128-10.

EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0. 2019.

Castro B. E., Berrio M., Vargas M. L., Carvajal L. P., Millan L. V., Rios R., Hernandez A. K., Rincon S., Cubides P., Forero E., Dinh A., Seas C., Munita J. M., Arias C. A., Reyes J., Diaz L. Detection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America. J Antimicrob Chemother. 2020 Sep 1; 75 (9): 2424–2431. doi: 10.1093/jac/dkaa221. PMID: 32562543; PMCID: PMC7443737.

Hourigan D., Stefanovic E., Hill C., Ross R. P. Promiscuous, persistent and problematic: insights into current enterococcal genomics to guide therapeutic strategy. BMC Microbiol. 2024 Mar 28; 24 (1): 103. doi: 10.1186/s12866-024-03243-2.

Guffey A. A., Loll P. J. Regulation of resistance in vancomycin-resistant enterococci: the VanRS two-component system. Microorganisms. 2021 Sep 25; 9 (10): 2026. doi: 10.3390/microorganisms9102026.

O'Toole R. F., Leong K. W. C., Cumming V., Van Hal S. J. Vancomycin-resistant Enterococcus faecium and the emergence of new sequence types associated with hospital infection. 123Res Microbiol. 2023 May; 174 (4): 104046. doi: 10.1016/j.resmic.2023.104046. Epub 2023 Feb 27.

Turner A. M., Lee J. Y. H., Gorrie C. L., Howden B. P., Carter G. P. genomic insights into last-line antimicrobial resistance in multidrug-resistant staphylococcus and vancomycin-resistant enterococcus. Front Microbiol. 2021 Mar 16; 12: 637656. doi: 10.3389/fmicb.2021.637656.

Sadowy E. Mobile genetic elements beyond the VanB-resistance dissemination among hospital-associated enterococci and other Grampositive bacteria. Plasmid. 2021 Mar; 114: 102558. doi: 10.1016/j.plas-mid.2021.102558. Epub 2021 Jan 17.

Caddey B., Shaukat W., Tang K. L., Barkema H. W. Vancomycin-resistant Enterococcus prevalence and its association along the food chain: a systematic review and meta-analysis. J Antimicrob Chemother. 2025 Apr 2; 80 (4): 908–918. doi: 10.1093/jac/dkaf008.

Ribes-Martínez L., Muñoz-Egea M. C., Yuste J., Esteban J., García-Quintanilla M. Bacteriophage therapy as a promising alternative for antibiotic-resistant Enterococcus faecium: advances and challenges. Antibiotics (Basel). 2024 Nov 23; 13 (12): 1120. doi: 10.3390/antibiotics13121120.

Jolley K. A., Bray J. E., Maiden M. C. J. Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications. Wellcome Open Res. 2018; 3: 124. doi: 10.12688/wellcomeopenres.14826.1.

The authors declare that there are no conflicts of interest present.